Table 3.

GPs’ choices of prescribing and deprescribing related to their perception of the RBR for females with multiple chronic diseases and multiple prescription drugsa

GPs judging the RBR to be unfavourablebGPs reporting that stopping is requiredcGPs choosing not to stop the drug while judging its RBR to be unfavourable
Treatmentn/N (%)n/N (%)n/N (%)
Lorazepam929/1025 (90.6)934/1032 (90.5)70/1183 (5.9)
Paracetamol and tramadol697/1016 (68.6)562/1011 (55.6)176/1183 (14.9)
Amitriptyline785/1010 (77.7)673/1006 (66.9)147/1183 (12.4)
Rosuvastatind135/477 (28.4)124/487 (25.4)38/1183 (3.2)
  • a Weighted data.

  • b Among the GPs reporting that some prescription drugs presented more risks than benefits (88.6% of all responding GPs).

  • c Among the GPs reporting that some prescription drugs should be stopped (90.0% of all responding GPs).

  • d Among the GPs questioned about a version of the clinical vignette, including a history of stroke. RBR = risk–benefit ratio.